Omeprazol Mylan (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Mylan, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease and to support Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Omeprazol Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Omeprazole is indicated for several acid‑related disorders where suppression of gastric acid is required.

- Gastroesophageal reflux disease (GERD): alleviates heartburn and regurgitation by reducing acid exposure in the esophagus. - Erosive esophagitis: promotes healing of inflamed esophageal tissue and prevents further damage. - Peptic ulcer disease: facilitates ulcer healing and reduces risk of recurrence by maintaining a less acidic gastric environment. - Helicobacter pylori eradication therapy: enhances the effectiveness of antibiotic regimens by creating a less favorable pH for bacterial survival.

Omeprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild pain or pressure in the head. - Diarrhea: loose, watery stools. - Nausea: feeling of sickness or urge to vomit. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: excess gas in the gastrointestinal tract. - Constipation: infrequent or difficult bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis): swelling, rash, difficulty breathing. - Clostridium difficile-associated diarrhea: severe colitis with watery stools. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Elevated liver enzymes: potential indication of liver injury. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: serious skin blistering. - Interstitial nephritis: inflammation of kidney tissue.

Before initiating omeprazole therapy, several safety considerations should be evaluated. - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic status: use caution in patients with liver disease. - Review concomitant medications: potential interactions may require monitoring. - Monitor long‑term use: prolonged therapy is linked to increased risk of bone fracture and vitamin B12 deficiency. - Use caution in pregnancy: benefits should outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Omeprazole can affect the pharmacokinetics of several drugs, leading to clinically relevant interactions.

Major Interactions (Avoid): - Rilpivirine, atazanavir, and ketoconazole: reduced absorption and efficacy when taken with omeprazole. - Clopidogrel: omeprazole may diminish its antiplatelet activation. - Warfarin: increased anticoagulant effect may occur, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Digoxin: higher serum levels may be observed; monitor for toxicity. - Methotrexate: reduced clearance can increase toxicity, especially at high doses. - HIV protease inhibitors (e.g., indinavir): altered plasma concentrations may necessitate dose adjustments.